Efficacy of targeted therapy for lung cancer patients included in IMPRESS-Norway, and precision cancer medicine in hard-to-treat rare cancers in the MATRIX-RARE study.
Schytte T, Knap MM, Kristiansen C, Appelt AL, Khalil A, Peucelle C, Lutz CM, Møller DS, Sande EPS, Sundby F, Persson G, Schmidt H, Land LH, Rogg L, Pøhl M, Lund MD, Nielsen M, Levin N, Hansen O, Thing RS, Borissova S, Halvorsen T, Nielsen TB, Hansen TS, Haakensen VDet al.(2025) Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non-Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial J Clin Oncol, JCO2401386(in press) DOI 10.1200/JCO-24-01386, PubMed 40249893
Nyen JE, Booth AØ, Husby Ø, Bugge C, Engebretsen I, Oteiza F, Helland Å, Fjellbirkeland L, Brustugun OT, Grønberg BH(2025) Corrigendum: Targeted treatment and survival in advanced non-squamous non-small cell lung cancer patients - a nationwide and longitudinal study Front Oncol, 15, 1595028 DOI 10.3389/fonc.2025.1595028, PubMed 40206591
Bergholtz H, Norum JH, Lien TG, Skrede ML, Garred Ø, Sørlie T(2025) B cells and energy metabolism in HER2-positive DCIS: insights into breast cancer progression from spatial-omics analyses Breast Cancer Res, 27(1), 44 DOI 10.1186/s13058-025-01990-2, PubMed 40119362
